Evaluating epilepsy management in an onchocerciasis-endemic area: Case of Maridi, South Sudan.

Burden Epilepsy Ivermectin Nodding syndrome Onchocerciasis Treatment

Journal

Seizure
ISSN: 1532-2688
Titre abrégé: Seizure
Pays: England
ID NLM: 9306979

Informations de publication

Date de publication:
06 May 2024
Historique:
received: 05 12 2023
revised: 30 04 2024
accepted: 01 05 2024
medline: 8 5 2024
pubmed: 8 5 2024
entrez: 7 5 2024
Statut: aheadofprint

Résumé

The epilepsy prevalence in Maridi County, South Sudan, in 2018 was 43.8 (95% CI: 40.9-47.0) per 1000 persons; 85.2% of the identified persons with epilepsy (PWE) met the criteria of onchocerciasis-associated epilepsy. To address this health problem, an epilepsy clinic was established at Maridi County Hospital in 2020. In August 2023, the impact of the clinic on the lives of PWE and their families was evaluated. At the Maridi epilepsy clinic, data routinely collected by primary healthcare workers as part of patient care was reviewed. We also analyzed findings from two household surveys conducted in 2018 and 2022, which assessed the impact of the clinic on epilepsy care. Moreover, four households, each with four PWE, were visited in a high epilepsy prevalence area. PWE were examined by a neurologist, and in-depth interviews were conducted with family members. The proportion of PWE on anti-seizure medication increased by 39.7% (95%CI: 35.3-44.2) between 2018 and 2022. The proportion of PWE reporting daily seizures decreased from 27.3% in 2018 to 5.3% in 2022. Of the 754 PWE seen in the clinic in July 2023, only 17 (2.3%) reported side effects. During household visits in July 2023, 13/173 (7.5%) of the visited PWE were found without remaining anti-seizure medication. A high level of epilepsy-related stigma was observed in all visited households. The Maridi epilepsy clinic positively impacted the lives of PWE in Maridi. Similar initiatives should be accessible for all PWE living in onchocerciasis-endemic areas. Evidence-based information about OAE is needed to decrease misconceptions and epilepsy-related stigma.

Identifiants

pubmed: 38714396
pii: S1059-1311(24)00133-X
doi: 10.1016/j.seizure.2024.05.001
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare no competing interests.

Auteurs

Olivia Kamoen (O)

Department of Neurology, Heilig Hart Ziekenhuis, Lier, Belgium.

Stephen Raimon Jada (SR)

Amref Health Africa, Juba, South Sudan.

Jacopo Mattia Rovarini (JM)

Amref Health Africa, Juba, South Sudan.

Gasim Abd-Elfarag (G)

Access for Humanity, Juba, South Sudan; School of Public Health, University of Juba, Juba, South Sudan; Health and Social Sciences Research Institute-South Sudan, Juba, South Sudan.

Luís-Jorge Amaral (LJ)

Global Health Institute, University of Antwerp, Antwerp, Belgium.

Yak Bol (Y)

Neglected Tropical Disease Programme, Ministry of Health, Juba, South Sudan.

Joseph Nelson Siewe Fodjo (JN)

Global Health Institute, University of Antwerp, Antwerp, Belgium.

Robert Colebunders (R)

Global Health Institute, University of Antwerp, Antwerp, Belgium. Electronic address: robert.colebunders@uantwerpen.be.

Classifications MeSH